(NASDAQ: LPTX) Leap Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Leap Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast LPTX's revenue for 2026 to be $247,545,612, with the lowest LPTX revenue forecast at $247,545,612, and the highest LPTX revenue forecast at $247,545,612. On average, 1 Wall Street analysts forecast LPTX's revenue for 2027 to be $1,192,344,698, with the lowest LPTX revenue forecast at $1,192,344,698, and the highest LPTX revenue forecast at $1,192,344,698.
In 2028, LPTX is forecast to generate $1,149,478,049 in revenue, with the lowest revenue forecast at $1,149,478,049 and the highest revenue forecast at $1,149,478,049.